The U.K.'s National Institute for Health and Care Excellence rejected the use of Celgene's Imnovid, or pomalidomide, as a third-line treatment for multiple myeloma because the drug's benefits failed to justify its high price. Celgene said it will continue working with NICE and the Department of Health to ensure patient access to pomalidomide.
The FDA has approved Celgene's Pomalyst, or pomalidomide, as treatment for patients with multiple myeloma who have stopped responding to other therapies. Pomalyst is intended to strengthen the immune system in blocking and eliminating cancer cells. The drug's label will include a warning that it can cause clots and that it should not be used by pregnant women because of the risk for birth defects.
More than 150 reptile and amphibian species are thriving on the remote Philippine island of Luzon, according to a species catalog published in the journal ZooKeys. Many of the creatures found in the Sierra Madre Mountains are native to the region, and more than one-third don't belong to a taxonomy, suggesting that they may be completely new species, researchers say.
Research that examines how the world's saltiest lake, a landlocked body of water in Antarctica, remains so salty could be used to understand how Mars once created its own lakes. The study, published in Scientific Reports, looked at 16,000 time-lapsed photos and discovered that Don Juan Pond remains high in salt because of water tracks created by salt in the soil that absorbs moisture in the air. Researchers believe the process is similar to the environment on Mars and may be how the Red Planet formed lakes in the past.
The FDA approved Celgene's Abraxane, or paclitaxel, to treat nonsmall-cell lung cancer that has locally advanced or spread to other body parts, in combination with carboplatin. Abraxane is indicated for patients who are not candidates for radiation therapy or curative surgery.